Surrogate endpoint analysis: an exercise in extrapolation.
暂无分享,去创建一个
[1] B. Kramer,et al. The risky reliance on small surrogate end point studies when planning a large prevention trial , 2013, Journal of the Royal Statistical Society. Series A,.
[2] S. Baker. Paradoxes in Carcinogenesis Should Spur New Avenues of Research: An Historical Perspective , 2012 .
[3] James Y. Dai,et al. A unified procedure for meta-analytic evaluation of surrogate end points in randomized clinical trials. , 2012, Biostatistics.
[4] B. Dunn,et al. Biomarkers as surrogate endpoints in cancer trials. , 2012, Seminars in oncology nursing.
[5] K. Johnson,et al. Is blood pressure reduction a valid surrogate endpoint for stroke prevention? an analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the biomarker-surrogacy (BioSurrogate) evaluation , 2012, BMC Medical Research Methodology.
[6] D. Sargent,et al. Predicting Treatment Effect from Surrogate Endpoints and Historical Trials: An Extrapolation Involving Probabilities of a Binary Outcome or Survival to a Specific Time , 2012, Biometrics.
[7] Debashis Ghosh,et al. Meta‐analysis for Surrogacy: Accelerated Failure Time Models and Semicompeting Risks Modeling , 2012, Biometrics.
[8] Jeremy MG Taylor,et al. Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials. , 2011, Biostatistics.
[9] Miguel A Hernán,et al. The hazards of hazard ratios. , 2010, Epidemiology.
[10] Tom Greene,et al. Related Causal Frameworks for Surrogate Outcomes , 2009, Biometrics.
[11] Michael LeBlanc,et al. Interim futility analysis with intermediate endpoints , 2008, Clinical trials.
[12] D. Sargent,et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] John A. Baron,et al. The framing effect of relative and absolute risk , 1993, Journal of General Internal Medicine.
[14] Steven Woloshin,et al. Ratio measures in leading medical journals: structured review of accessibility of underlying absolute risks , 2006, BMJ : British Medical Journal.
[15] C. Weir,et al. Statistical evaluation of biomarkers as surrogate endpoints: a literature review , 2006, Statistics in medicine.
[16] Laurence S. Freedman,et al. Commentary on Assessing surrogates as trial endpoints using mixed models by E. L. Korn, P. S. Albert and L. M. McShane , 2005 .
[17] Paul S Albert,et al. Assessing surrogates as trial endpoints using mixed models , 2005, Statistics in medicine.
[18] B. Trock,et al. A Pilot Study to Establish a Clinical Model to Perform Phase II Studies of Breast Cancer Chemopreventive Agents in Women at High Risk with Biomarkers as Surrogate Endpoints for Activity , 2004, Clinical Cancer Research.
[19] S. Lam,et al. A Randomized Phase IIb Trial of Pulmicort Turbuhaler (Budesonide) in People with Dysplasia of the Bronchial Epithelium , 2004, Clinical Cancer Research.
[20] M. Buyse,et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] P. Philip,et al. Phase II study of capecitabine, irinotecan, and celecoxib in advanced colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Geert Molenberghs,et al. The validation of surrogate end points by using data from randomized clinical trials: a case‐study in advanced colorectal cancer , 2004 .
[23] R. Labianca,et al. Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] B. Kramer,et al. A perfect correlate does not a surrogate make , 2003, BMC medical research methodology.
[25] H. Wainer. Visual Revelations , 2002 .
[26] D. Rubin,et al. Principal Stratification in Causal Inference , 2002, Biometrics.
[27] S G Baker,et al. Good for women, good for men, bad for people: Simpson's paradox and the importance of sex-specific analysis in observational studies. , 2001, Journal of women's health & gender-based medicine.
[28] R J Carroll,et al. On meta-analytic assessment of surrogate outcomes. , 2000, Biostatistics.
[29] G. Molenberghs,et al. The validation of surrogate endpoints in meta-analyses of randomized experiments. , 2000, Biostatistics.
[30] G. Molenberghs,et al. Criteria for the validation of surrogate endpoints in randomized experiments. , 1998, Biometrics.
[31] P. Flandre. Analysing survival in the presence of an auxiliary variable. , 1998, Statistics in medicine.
[32] M J Daniels,et al. Meta-analysis for the evaluation of potential surrogate markers. , 1997, Statistics in medicine.
[33] D. Schoenfeld,et al. Analysing survival in the presence of an auxiliary variable. , 1994, Statistics in medicine.
[34] M S Pepe,et al. Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. , 1994, Statistics in medicine.
[35] D. Albanes,et al. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. , 1994, The New England journal of medicine.
[36] S. Ellenberg. Surrogate endpoints. , 1993, British Journal of Cancer.
[37] C D Naylor,et al. Measured Enthusiasm: Does the Method of Reporting Trial Results Alter Perceptions of Therapeutic Effectiveness? , 1992, Annals of Internal Medicine.
[38] Margaret S. Pepe,et al. Inference using surrogate outcome data and a validation sample , 1992 .
[39] R Simon,et al. Statistical model to determine the relationship of response and survival in patients with advanced ovarian cancer treated with chemotherapy. , 1992, Journal of the National Cancer Institute.
[40] R M Arnold,et al. Absolutely relative: how research results are summarized can affect treatment decisions. , 1992, The American journal of medicine.
[41] B. Graubard,et al. Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.
[42] H. Chernoff,et al. Locally optimal design for comparing two probabilities from binomial data subject to misclassification , 1990 .
[43] R. Prentice. Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.
[44] Juni Palmgren,et al. Precision of double sampling estimators for comparing two probabilities , 1987 .